sing a neuroprotective drug to treat patients who have a serious type of brain bleeding caused by a rupture of a weakened blood vessel (aneurysm)

Phase 4

• Conditions: europrotection in patients with severe aneurysmal subarachnoidal haemorhage after endovascular treatment of ruptured aneurysm; Circulatory System

• Registration Number: ISRCTN16818128
• Lead Sponsor: niversity Hospital Centre Zagreb

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-10
• Last Update Posted: 25 July 2023
• Study Completion: 2025-01-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Aneurysmal subarachnoidal haemorrhage
2. Inital Hunt-Hess grade 3 or higher
3. Endovasculary secured aneurysm
4. Availability to add-on treatment not more than 24 hours after embolisation

Exclusion Criteria

1. Known allergy to Cerebrolysine
2. Refusal of participation in the study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional outcome of the patients measured with mRS 90 days after the bleeding

Secondary Outcome Measures

Name	Time	Method
1. Development of delayed neurological deficit during 21 days after the bleeding, verified by neuroimaging<br>2. Developement of the vasospasms during 14 days after the bleeding during TCD monitoring<br>3. Mortality after 90 days measured using patient records<br>4. Safety of Cerebrolysine (adverse events) up to end of study